Objective: Development of obesity and type-2-diabetes (T2D) are associated with gut microbiota 18 (GM) changes. The gut viral community is predominated by bacteriophages (phages), which are 19 viruses that attack bacteria in a host-specific manner. As a proof-of-concept we demonstrate the 20 efficacy of faecal virome transplantation (FVT) from lean donors for shifting the phenotype of obese 21 mice into closer resemblance of lean mice. 22 Design: The FVT consisted of viromes extracted from the caecal content of mice fed a low-fat (LF) 23 diet for fourteen weeks. Male C57BL/6NTac mice were divided into five groups: LF (as control), 24 high-fat diet (HF), HF+Ampicillin (Amp), HF+Amp+FVT and HF+FVT. At week six and seven of the 25 study the HF+FVT and HF+Amp+FVT mice were treated with FVT by oral gavage. The Amp 26 groups were treated with ampicillin 24 h prior to first FVT treatment. 27
Significance of this study
What is already known about this subject?
40
• Obesity and type-2-diabetes (T2D) are associated with gut microbiota (GM) dysbiosis. 41
• Faecal microbiota transplant from lean donors has previously shown potential in treating 42 obesity and T2D. 43
• Patients suffering from recurrent Clostridium difficile infections (rCDI) have been cured with 44 sterile filtered donor faeces (containing enteric viruses and no bacteria), here defined as 45 faecal virome transplantation (FVT) . 46
What are the new findings?
47
• FVT from lean donors lead to decreased weight gain and normalised blood sugar tolerance 48 in a diet-induced obesity (DIO) mouse model. 49
• FVT significantly changed the bacterial and viral GM component, as well as the plasma 50 metabolome and the expression profiles of obesity and T2D associated genes. 51
• Initial treatment with ampicillin prior FVT seems to counteract the beneficial effects 52 associated with FVT. 53 How might it impact on clinical practice in the foreseeable future?
54
• We here show a proof-of-concept, providing a solid base for designing a clinical study of 55 FVT targeting obesity and T2D in humans. This is further augmented by the increased 56 safety related to FVT, since bacteria and other microorganisms are removed from the donor 57 faeces, and therefore minimises the risk of disease transmission. 58
• These findings highlight the potential application of FVT treatment of various diseases 59 related to GM dysbiosis and further support the vital role of the viral community in 60 maintaining and shaping the GM. 61
INTRODUCTION 63
Obesity and type-2-diabetes (T2D) constitute a world-wide health threat [1] . During the last decade 64 it has become evident that certain diseases, including obesity and T2D, are associated with gut 65 microbiota (GM) dysbiosis [2] . Interestingly, germ free (GF) mice do not develop diet-induced-66 obesity (DIO) [3] , but when exposed to faecal microbiota transplantation (FMT) from an obese 67 human donor they increase their body weight significantly more compared to GF mice exposed to 68 FMT from a lean donor [4] . At present FMT is widely used to efficiently treat recurrent Clostridium 69 difficile infections (rCDI) [5] , and is suggested to have therapeutic potential against metabolic 70 syndrome, a condition related to obesity and T2D [6] . FMT is considered as a safe treatment, 71 however, safety issues remain since screening methods cannot fully prevent adverse effects 72 caused by disease transmission from the donor faeces [7] . A failure in the screening procedure 73 caused recently in a death (June 2019) of a patient following FMT[8] due to a bacterial infection. 74
The gut viral community (virome) is dominated by prokaryotic viruses[9], also called 75 bacteriophages (phages), which are viruses that attack bacteria in a host-specific manner [10] . 76
During recent years, evidence has mounted that the gut virome plays a key role in shaping the 77 composition of the GM [11, 12] as well as influencing the host metabolome [13] . Interestingly, rCDI 78 have been successfully treated with a transfer of filtered donor faeces (containing phages, but no 79 intact bacterial cells) [14] . Five out of five patients were successfully treated [14] . This approach is 80 referred to as faecal virome transplantation (FVT). Further, antibiotic treatment alters the GM 81 composition, but Draper et al. 2019 recently showed that the murine GM can be reshaped with 82
FVT after antibiotic treatment [15] . 83 DIO mice is a common animal model of metabolic syndrome, including symptoms such as obesity 84 and insulin resistance/pre-T2D [16] . With C57BL/6NTac mice as the model, we hypothesised that 85 FVT (originating from lean healthy donor mice) treatment of DIO mice would change the GM 86 composition and directly or indirectly counteract the symptoms of obesity and T2D. To the best of 87 our knowledge, this is the first study investigating the effect of FVT targeting obesity and T2D. 88
METHODS

90
Detailed methods are enclosed in the online supplementary materials. 91
Animal study design 92
Forty male C57BL/6NTac mice (Taconic Biosciences A/S, Lille Skensved, Denmark) were divided 93 into 5 groups at 5 weeks of age: low-fat diet (LF, as lean control), high-fat diet (HF), HF+Ampicillin 94 (Amp), HF+Amp+faecal virome transplantation (FVT) and HF+FVT ( Figure 1 ). For thirteen weeks 95 mice were fed ad libitum a HF diet (Research Diets D12492, USA) or a LF diet (Research Diets 96 D12450J, USA). After six weeks on their respective diets, the HF+FVT and HF+Amp+FVT mice 97
were treated twice with 0.15 mL FVT by oral gavage with a one-week interval (week 6 and 7) 98 between the FVT. On the day before the first FVT inoculation the HF+Amp and HF+Amp+FVT 99 animals were treated with a single dose of ampicillin (1 g/L) in the drinking water. The FVT viromes 100 were extracted from the caecal content of eighteen mice fed a LF diet for 14 weeks, that were 101 earlier isolated, sequenced, and analysed [17] . 
Gene expression assay 145
Genes investigated for expression analysis were selected based on relevant pathways for each 146 tissue. For the liver, genes involved in metabolic pathways (triglyceride, carbohydrate, bile and cholesterol metabolism) and inflammation were selected. For the ileum, genes involved in 148 inflammation, gut microbiota signalling and gut barrier function were selected [28, 29] . Primer 149 sequences are listed in Table S2 . qPCR was performed using the Biomark HD system (Fluidigm 150 Corporation) on 2x 96.96 IFC chips on pre-amplified cDNA duplicates following the instructions of 151 the manufacturer with minor adjustments as previously described [30] . Gene expression data was 152 analysed in R using linear models (one-way ANOVA) with either HF or LF as control groups. 153 
Blood plasma metabolome analysis
273
DISCUSSION
274
FVT has been successfully used to treat rCDI [14] , an effect probably mediated by the ability of FVT 275 to reshape the GM of the recipient. However, several parameters differentiate obesity and T2D 276 from rCDI to which is characterised by a clonal infection highly susceptible to viral attack, a highly 277 dysbiotic GM and the extensive use of antibiotics [14] . Here, we show that FVT from lean mice 278 donors to obese recipients successfully counteracts some of the adverse effects of a HF diet with a 279 decrease in body weight gain (p < 0.0034) and a normalised blood glucose tolerance relative to 280 mice fed a LF diet. Indeed, HF+FVT mice showed exactly the same response in an OGTT as the 281 LF mice (p > 0.842, Figure 2 was clearly increased (Figure 3g ). Overall, these findings indicate that FVT treatment affects the expression of genes involved in stimulating appetite, blood glucose tolerance, and whole-body and 321 energy homeostasis. 322
An extensive study of metabolic syndrome in humans, showed strong correlations between certain 323 blood plasma metabolites and the GM component [50] , and some of these correlations appear 324 specific to the pre-diabetic state [50] . Furthermore, blood plasma metabolome seem to predict the 325 Figure S7 and S8. Zuo et al.[54] investigated how the phage community could be related to the effect of FMT against 345 rCDI and found that a few patients did not respond on the treatment. The common denominator of 346 the patients that did respond on the FMT treatment was that the Caudovirales richness in the 347 donor faeces was higher than the Caudovirales richness in the recipient, whereas most of the non-348 responder recipients had a higher Caudovirales richness than the donor. Based on these findings, In conclusion, we here demonstrate the use of FVT targeting obesity and T2D in an animal model. 364
Although the study is a proof-of-concept, our findings highlight the potential of using phage-365 mediated therapy against obesity and T2D[6] that represents a world-wide health threat [1] . 366
Acknowledgement 367
Thanks to Julie Mou Larsen for assisting with sampling of mouse tissue and associated method 368 description. In addition, we thank Helene Farlov, Mette Nelander at Section of Experimental Animal 369
Models and Liv de Vries at Section for Microbiology and Fermentation (University of Copenhagen, 370
Denmark) for taking care of the animals. We thank Helle Keinicke and Marina Kjaergaard 371
Gerstenberg for selecting the genes and providing the primers for the liver gene expression panel. 
